MannKind (MNKD) investors got a little bit of insight regarding its PAH drug candidate TrepT (Dryvaso) from United Therapeutics (UTHR) on its Q4 conference call held Wednesday morning. The most important nuggets of information from United Therapeutics which relate to MannKind can be found in the 10K.
Under our agreement with MannKind, we are responsible for global development, regulatory and commercial activities related to Treprostinil Technosphere. We plan to commence a clinical study (called BREEZE) during the first half of 2019 to evaluate the safety of switching PAH patients